Medically reviewed by Jurairat J. Molina, MD HFA-based metered-dose inhalers (MDIs) contain a propellant to deliver the ...

Phillips Medisize adds market-leading inhalation capabilities to its existing suite of drug delivery device design and ...

Phillips Medisize parent company Molex has completed its acquisition of Vectura from a subsidiary of cigarette maker Philip ...

Objective: To identify subject characteristics that may be predictive of intentional dumping of metered-dose inhalers (MDIs) during a clinical trial. Design: Nebulizer Chronologs (NCs; Medtrac ...

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

Guidance makes it clear that there should be no blanket switch from a preventer metered dose inhaler (MDI) to a dry powder inhaler (DPI), and that any changes should be done carefully and with ...

Budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol ...

Expands Phillips Medisize’s inhalation drug delivery capabilities.

Budesonide 160mcg, glycopyrrolate 9mcg, formoterol fumarate 4.8mcg; per inhalation; metered-dose inhaler with dose counter ... and formoterol fumarate [GFF MDI 18 mcg/9.6 mcg], budesonide and ...

New Delhi, Nov 22 () Drug maker Lupin on Friday said it has launched a device to track usage pattern of metered-dose inhalers (MDI) by patients suffering from chronic respiratory diseases.

a twice-daily metered dose inhaler, and fluticasone-umeclidinium-vilanterol, a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score ...